Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Science. 2013 Feb 1;339(6119):580-4. doi: 10.1126/science.1228522.
Epithelial-mesenchymal transition (EMT) of adherent epithelial cells to a migratory mesenchymal state has been implicated in tumor metastasis in preclinical models. To investigate its role in human cancer, we characterized EMT in circulating tumor cells (CTCs) from breast cancer patients. Rare primary tumor cells simultaneously expressed mesenchymal and epithelial markers, but mesenchymal cells were highly enriched in CTCs. Serial CTC monitoring in 11 patients suggested an association of mesenchymal CTCs with disease progression. In an index patient, reversible shifts between these cell fates accompanied each cycle of response to therapy and disease progression. Mesenchymal CTCs occurred as both single cells and multicellular clusters, expressing known EMT regulators, including transforming growth factor (TGF)-β pathway components and the FOXC1 transcription factor. These data support a role for EMT in the blood-borne dissemination of human breast cancer.
上皮-间充质转化(EMT)是指贴壁上皮细胞向迁移的间充质状态的转化,这一过程被认为与临床前模型中的肿瘤转移有关。为了研究其在人类癌症中的作用,我们对来自乳腺癌患者的循环肿瘤细胞(CTC)中的 EMT 进行了特征描述。罕见的原发性肿瘤细胞同时表达间充质和上皮标志物,但间充质细胞在 CTC 中高度富集。对 11 名患者的连续 CTC 监测表明,间充质 CTC 与疾病进展有关。在一名指数患者中,这些细胞命运之间的可逆转变伴随着对治疗和疾病进展的每一次反应循环。间充质 CTC 以单细胞和多细胞簇的形式出现,表达已知的 EMT 调节剂,包括转化生长因子(TGF)-β途径成分和 FOXC1 转录因子。这些数据支持 EMT 在人乳腺癌血源性播散中的作用。
BMC Cancer. 2014-6-28
J Hematol Oncol. 2025-8-22
Nat Rev Clin Oncol. 2025-7-22
Nat Rev Cancer. 2012-5-11
Int J Cell Biol. 2012
Cell. 2012-1-20
Cancer Discov. 2011-11-3